IM Cannabis, Organigram And Other Hot Cannabis Stocks Soon To Report Earnings, What Investors Need To Know Now
Portfolio Pulse from Jelena Martinovic
Several cannabis companies, including IM Cannabis, cbdMD, Entourage Health, and Organigram Holdings, are set to report their earnings for the second quarter of 2024. IM Cannabis will discuss its results and recent share consolidation plan, cbdMD will address its operational losses and cost-cutting measures, Entourage Health will provide an update on its financial health, and Organigram Holdings will report its earnings and discuss its strategic investments in the European market.
August 06, 2024 | 5:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Entourage Health will report Q2 2024 earnings and provide an update on its financial health, showing a 9% YoY revenue increase.
Despite a YoY revenue increase, the significant drop in share price indicates investor concerns, leading to a neutral short-term impact.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 100
NEUTRAL IMPACT
cbdMD will report Q3 2024 earnings and discuss its cost-cutting measures aimed at saving $2.4 million annually.
While the cost-cutting measures are positive, the increase in operational losses may offset the benefits in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
IM Cannabis will report Q2 2024 earnings and discuss its recent share consolidation plan, which reduced outstanding shares and improved liquidity.
The share consolidation plan is likely to attract institutional investors and improve liquidity, which is positive for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Organigram Holdings will report Q3 2024 earnings and discuss its strategic investments in the European market.
The strategic investments in the European market are likely to be viewed positively by investors, boosting the stock in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100